Complement-mediated immunotherapy to the Oral Squamous Cell Carcinoma with Cetuximab

点击翻译按钮获取中文摘要

To conserve both form and function in the oral area, effective and selective drugs against oral cancer will be required. We focused on Cetuximab, that is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing cancer. Complement deposition (C3) on HSC4 (human oral squamous cell carcinomas cell line) by incubation with Cetuximab and human serum was slightly enhanced. On the other hands, complement inhibitors expressed on tumor cells provide a hindrance to the therapeutic efficacy of some monoclonal antibodies. We investigated a strategy to amplify complement activation on tumor cells and overwhelm complement inhibitor function. Complement deposition and lysis of HSC4 cells by incubation with Cetuximab and human serum was enhanced in the presence of CR2-Fc. CR2-Fc enhances the therapeutic efficacy of antibody therapy and may provide particular benefits under conditions of limiting antibody concentration or low tumor antigen density.